Particle.news

Download on the App Store

Meta-Analysis Reveals Opposing Breast Cancer Risks of Hormone Replacement Therapy in Women Under 55

Clinicians should tailor HRT recommendations based on therapy type, duration, patient age, surgical history.

Image
Image
Image

Overview

  • Oestrogen-only therapy was linked to a 14% reduction in young-onset breast cancer risk, with stronger protection when started at younger ages or used longer.
  • Combined oestrogen-progestin therapy was associated with a 10% increased breast cancer risk, rising to 18% after more than two years of use.
  • Women with an intact uterus or ovaries experienced higher risk from combined therapy compared to those who had undergone hysterectomy or oophorectomy.
  • The Lancet Oncology meta-analysis pooled data from 459,476 women aged 16 to 54 across North America, Europe, Asia and Australia.
  • Health bodies and clinicians are integrating these findings into personalized guidelines, affirming unopposed oestrogen only for post-hysterectomy patients.